Board of Directors

Bill Carson, M.D.

Chairman of the Board, Otsuka Pharmaceutical Development & Commercialization, Inc.

Bill Carson, M.D. is the Chairman of the Board of Otsuka Pharmaceutical Development & Commercialization, Inc. and was the President & CEO from 2010 through 2019.

Since his appointment in 2010 as the President & CEO, he led the development efforts of compounds in neuroscience, cardio-renal, and oncology, and was instrumental in the development and registration of ABILIFY MAINTENA® (aripiprazole) for extended-release injectable suspension and SAMSCA® (tolvaptan).

He joined Otsuka in 2002 as a board-certified psychiatrist and served as OPDC’s Senior Vice President, Global Clinical Development, overseeing the development of Otsuka-discovered compounds. During his career at Otsuka and earlier at Bristol-Myers Squibb (BMS), he was one of the key drivers in the development and commercialization of ABILIFY® (aripiprazole). He received an A.B. degree in history and science from Harvard University and an M.D. degree from Case Western Reserve University.

Daniel Dornbusch, MPH MBA

Chief Executive Officer

Daniel Dornbusch has worked in the biotechnology industry for over 20 years for large pharmaceutical, small biotechnology, and diagnostics companies in roles including business development, mergers and acquisitions, marketing, sales, commercial strategy, and product development. He most recently served as founder and CEO of Acteris, an immunoncology company located in San Francisco. Daniel previously served as Chief Commercial Officer at Nodality, a therapeutic development company focused in immunology, oncology and immunoncology. Before Acteris, Daniel worked at Novartis in business development and later assumed responsibility as the Commercial Director of the Western United States and Latin America for the Diagnostics Division. Previous to Novartis, Daniel held roles in business development at Cerimon Pharmaceuticals, led business development and sales for NMCR, an oncology strategy arm of AmerisourceBergen, and led a hematology marketing team at Genentech.

Daniel started his biotechnology career at the Genzyme Corporation and served in various roles including business development, product management, and corporate development. Daniel received his B.A. in Biology and English from Cornell University, M.S. from Tufts University School of Medicine and Emerson College, and M.B.A. from the Harvard Business School.

Henry Klingenstein

Partner, Artis Ventures

Henry Klingenstein is a Partner at ARTIS Ventures. Henry primarily covers healthcare technologies and contributes to deal sourcing, due diligence, and portfolio support. Prior to ARTIS, Klingenstein incubated Spur Laboratories, a computational medicine startup using machine learning algorithms for diagnostics, as a researcher in Sendhil Mullainathan’s lab at the University of Chicago. He also previously worked at Quid, an ARTIS portfolio company, where he focused on healthcare and industrial clients. Klingenstein holds an MBA from the Stanford Graduate School of Business and an AB from Harvard College. He was also a fellow at Longitude Capital.

Ashok Krishnamurthi

Managing Partner, GreatPoint Ventures

Ashok is a serial entrepreneur and investor focused on enterprise IT, and the intersection of computer science and life sciences. He also holds more than 20 patents in his name.

Most recently he founded two medical related companies: CAPP Medical, a liquid biopsy company for cancer diagnosis that he sold to Roche Diagnostics, and CiberMed, which focuses on biomarker discovery. Previously he founded Xsigo, a provider of advanced data center connectivity, which he sold to Oracle.

Prior to Xsigo, Ashok was one of the early leaders of Juniper Networks where he helped develop many of the products that power today’s internet, and which was one of the largest venture investment returns of all time. Ashok has also been an investor in a number of innovative companies like GoEuro, Reflektion, OttoQ, Veradocs, Falcon Systems, Robin Systems, and ScoreData, amongst others. He is on the board of ScoreData and various GPV portfolio companies.